Rationale for the luminal provision of butyrate in intestinal diseases
about
Gastrointestinal microflora, food components and colon cancer preventionHMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na(+)-coupled transporter for short-chain fatty acidsRestricted distribution of the butyrate kinase pathway among butyrate-producing bacteria from the human colonDifferential expression proteomics of human colon cancer.Calcium butyrate: Anti-inflammatory effect on experimental colitis in rats and antitumor propertiesThe actin-bundling protein fascin is overexpressed in inflammatory bowel disease and may be important in tissue repairThe bacterial fermentation product butyrate influences epithelial signaling via reactive oxygen species-mediated changes in cullin-1 neddylation.Microbes in gastrointestinal health and diseaseReduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces.Nutriose, a prebiotic low-digestible carbohydrate, stimulates gut mucosal immunity and prevents TNBS-induced colitis in piglets.Effects of medicated diet to eradicate Helicobacter spp. on growth, pathology, and infection status in Rag1-/- and nude miceTributyrin supplementation protects mice from acute ethanol-induced gut injury.Fermentation products of inulin-type fructans reduce proliferation and induce apoptosis in human colon tumour cells of different stages of carcinogenesis.Lactobacillus GG and tributyrin supplementation reduce antibiotic-induced intestinal injuryNon-digestible oligosaccharides and defense functions: lessons learned from animal models.Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis.Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes.Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease.Colonic butyrate- algesic or analgesic?Glycan complexity dictates microbial resource allocation in the large intestine.Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial.Expression profiling of cardiovascular disease.Influence of Butyrate Loaded Clinoptilolite Dietary Supplementation on Growth Performance, Development of Intestine and Antioxidant Capacity in Broiler Chickens.Sodium butyrate stimulates NHE8 expression via its role on activating NHE8 basal promoter activity.Effects of Liver Resection on Hepatic Short-Chain Fatty Acid Metabolism in HumansVitamin A deficiency impacts the structural segregation of gut microbiota in children with persistent diarrhea.The combined use of triacylglycerols containing medium-chain fatty acids and exogenous lipolytic enzymes as an alternative to in-feed antibiotics in piglets: concept, possibilities and limitations. An overview.Regulation of Candida albicans morphogenesis by fatty acid metabolites.Potential role of probiotic bacteria in the treatment and prevention of localised candidosis.Commensal Clostridia: leading players in the maintenance of gut homeostasis.Effect of resistant starch on the intestinal health of old dogs: fermentation products and histological features of the intestinal mucosa.Short-Chain Fatty Acids Regulate Secretion of IL-8 from Human Intestinal Epithelial Cell Lines in vitro.Inside Out: HIV, the Gut Microbiome, and the Mucosal Immune System.Analysis of the gut bacterial communities in beef cattle and their association with feed intake, growth, and efficiency.Bacterial monocultures, propionate, butyrate and H2O2 modulate the expression, secretion and structure of the fasting-induced adipose factor in gut epithelial cell lines.The HIV protease inhibitor ritonavir synergizes with butyrate for induction of apoptotic cell death and mediates expression of heme oxygenase-1 in DLD-1 colon carcinoma cells.Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids.Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity.Development of a semiquantitative degenerate real-time pcr-based assay for estimation of numbers of butyryl-coenzyme A (CoA) CoA transferase genes in complex bacterial samples.
P2860
Q24654943-2DABBDE6-534E-4BD5-B302-AFE872525E02Q28201997-D21625DE-1E33-448C-B324-1839B5719728Q28245395-6A9A485D-43F0-435E-88E9-606782AA2C95Q28251129-0DFCB515-1837-4AB9-8E25-4A80245A8525Q33232585-E54EE749-2FAF-41CE-B2ED-F2DBF3C689C6Q33733474-120592D8-CD18-4F95-ADF3-6E3206A6F97FQ33827631-201BD652-2667-414D-8C61-8073EA11D568Q33858114-2518B4D5-DF7F-429B-BC25-61936171A052Q33943525-9F815674-A677-4117-9046-6152864C928FQ34001633-4EAFCD0A-CCA5-4A77-B4A9-99305075D52FQ34020518-54E16445-2E8A-4C7D-A00B-BCC78BBD8726Q34027028-3324B22B-EE54-46A1-8318-D46B982EEE13Q34290107-A74E07A4-26E0-46BB-918E-3EAA90829038Q34604959-ED8CC686-08DF-4824-A91F-CA99E1E7C03FQ34695124-DD836D8C-344F-4275-BA62-1B417C7F9CE6Q34712441-C4E04D30-43FA-4D00-B471-01E3AF4F4AC6Q34733841-FDD0444D-6373-4CF1-AC96-CC87465ABFB5Q34779075-7A905EF9-4A58-4EBE-BE2C-0D4DD6C60CAEQ35220907-795D560B-D9DC-4D09-AE52-95189C8544D9Q35328232-101B158F-4181-4783-B3C1-F73CE7C3437EQ35816616-E098FD09-78F6-4A86-8256-2934A6EE2D5FQ35953414-8CAFCD9A-BEAD-4321-8C83-65F0B5E61064Q35978591-C7F5979A-018E-49EE-BFAF-1EF53ED3AEB3Q35996910-2EBC3E1F-4D7D-44D7-83DA-5B15F025EF55Q36066428-D261F369-DA77-4AB3-94D5-0CFDBD7623D3Q36189874-4E567EAA-5F36-4FCB-8629-A641F75088DCQ37247019-7EDC8413-8E95-422E-97AB-9298508C512BQ37352238-6D0B760E-E7C7-4DD3-B714-265F2A7858DDQ37582849-CF91C7A9-4163-402B-AC2D-80A76769141AQ37889385-E66F9333-AFE8-4C2E-9011-09F92325E3FCQ38128618-E3345587-E3EE-423E-942E-2BD648811D1DQ38818951-C43C6EA5-BB69-4E76-A92B-45A6D4CB2759Q38830276-F5126D2D-ADF9-4115-8C69-C7A4593F8330Q39030604-CF9A27EF-8869-404B-8250-89B3BFBF1C18Q39447416-3C4601D3-0ABC-425E-AC02-F5CA1682D56AQ39553474-17639C90-3B8F-406C-91C6-59277A9FC0AAQ40500029-C14385AD-BAC5-4F8F-BE0F-654827C37819Q40595373-6C1C8F11-D770-4D97-8564-5E77FA4534E5Q40778493-A77DBC5E-C533-4242-9BB2-1211FA471F27Q41887063-70189112-41B3-47B4-AAC9-54F747BA2B0D
P2860
Rationale for the luminal provision of butyrate in intestinal diseases
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Rationale for the luminal provision of butyrate in intestinal diseases
@ast
Rationale for the luminal provision of butyrate in intestinal diseases
@en
Rationale for the luminal provision of butyrate in intestinal diseases
@nl
type
label
Rationale for the luminal provision of butyrate in intestinal diseases
@ast
Rationale for the luminal provision of butyrate in intestinal diseases
@en
Rationale for the luminal provision of butyrate in intestinal diseases
@nl
prefLabel
Rationale for the luminal provision of butyrate in intestinal diseases
@ast
Rationale for the luminal provision of butyrate in intestinal diseases
@en
Rationale for the luminal provision of butyrate in intestinal diseases
@nl
P3181
P356
P1476
Rationale for the luminal provision of butyrate in intestinal diseases
@en
P2093
A Wächtershäuser
P2888
P304
P3181
P356
10.1007/S003940070020
P407
P577
2000-08-01T00:00:00Z